SG11201901125TA - Treatment of dementia - Google Patents
Treatment of dementiaInfo
- Publication number
- SG11201901125TA SG11201901125TA SG11201901125TA SG11201901125TA SG11201901125TA SG 11201901125T A SG11201901125T A SG 11201901125TA SG 11201901125T A SG11201901125T A SG 11201901125TA SG 11201901125T A SG11201901125T A SG 11201901125TA SG 11201901125T A SG11201901125T A SG 11201901125TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- aberdeen
- aberdeenshire
- wista
- institute
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Valve Device For Special Equipments (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111 010 1111 001110 11111111111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/041739 Al 08 March 2018 (08.03.2018) WI P0 I P C T (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every A61K 31/5415 (2006.01) A61K 31/55 (2006.01) kind of regional protection available): ARIPO (BW, GH, A61K 45/06 (2006.01) A61K 9/20 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, A61K 31/136 (2006.01) A61K 9/48 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61K 31/165 (2006.01) A61P 25/28 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, A61K 31/445 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/EP2017/071437 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 25 August 2017 (25.08.2017) Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (25) Filing Language: English (26) Publication Language: English Published: — with international search report (Art. 21(3)) (30) Priority Data: 1614834.8 01 September 2016 (01.09.2016) GB (71) Applicant: WISTA LABORATORIES LTD. [SG/SG]; 25 Bukit Batok Crescent, The Elitist #06-13, Singapore 658066 (SG). _ (71) Applicant (for MG only): HARRINGTON, Charles — Robert [GB/GB]; WisTa Laboratories Ltd., Institute of = Medical Sciences, Forresterhill, Aberdeen Aberdeenshire = AB25 2ZD (GB). Inventors: WISCHIK, Claude Michel; c/o WisTa Lab- (72) = oratories Ltd., Institute of Medical Sciences, Forresterhill, _= = Aberdeen Aberdeenshire AB25 2ZD (GB). SCHELTER, Bjorn Olaf; c/o University of Aberdeen, Institute for Corn- _ = plex Systems and Mathematical Biology, Meston Walk., Aberdeen Aberdeenshire AB24 3UE (GB). WISCHIK, Damon Jude; c/o Cambridge Big Data, Cavendish Labo- ratory, J.J. Thomson Avenue, Cambridge Cambridgeshire — = CB3 OHE (GB). STOREY, John Mervyn David; c/o WisTa Laboratories Ltd., Department of Chemistry, Meston = — = Walk, Old Aberdeen Aberdeenshire AB24 3UE (GB). — — Agent: KREMER, Simon et al.; Mewburn Ellis LLP, City (74) Tower, 40 Basinghall Street, London Greater London EC2V = 5DE (GB). = = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, — AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, — 1-1 01 M KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, IN TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1-1 71' 0 00 (54) Title: TREATMENT OF DEMENTIA 1-1 0 (57) : The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium ei compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic 0 Alzheimer's disease treatment (e.g. acetylcholinesterase and/or memantine).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901125TA true SG11201901125TA (en) | 2019-03-28 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901125TA SG11201901125TA (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (en) |
| EP (1) | EP3506904B1 (en) |
| JP (1) | JP7066679B2 (en) |
| KR (1) | KR102559354B1 (en) |
| CN (1) | CN109890391B (en) |
| AU (1) | AU2017318333B2 (en) |
| CA (1) | CA3034625A1 (en) |
| DK (1) | DK3506904T3 (en) |
| ES (1) | ES2847929T3 (en) |
| GB (1) | GB201614834D0 (en) |
| HR (1) | HRP20210162T1 (en) |
| MX (1) | MX2019002429A (en) |
| MY (1) | MY187564A (en) |
| PL (1) | PL3506904T3 (en) |
| PT (1) | PT3506904T (en) |
| SG (1) | SG11201901125TA (en) |
| SI (1) | SI3506904T1 (en) |
| WO (1) | WO2018041739A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3121169T3 (en) | 2006-07-11 | 2022-05-23 | Wista Laboratories Ltd. | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| CN112805008A (en) | 2018-07-26 | 2021-05-14 | 维斯塔实验室有限公司 | Optimal diaminophenothiazine dosage in a population |
| US20210193322A1 (en) | 2018-09-05 | 2021-06-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Network methods for neurodegenerative diseases |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| MXPA04011762A (en) * | 2002-05-31 | 2005-03-31 | Lundbeck & Co As H | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease. |
| HUE044355T2 (en) | 2004-09-23 | 2019-10-28 | Wista Lab Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| AU2007231124B2 (en) | 2006-03-29 | 2013-02-21 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
| SI2853293T1 (en) * | 2006-03-29 | 2018-03-30 | Wista Laboratories Ltd. | Thioninium compounds and their use |
| FR2899107B1 (en) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | USE OF (S) -ROSCOVITINE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
| PL3121169T3 (en) | 2006-07-11 | 2022-05-23 | Wista Laboratories Ltd. | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (en) | 2006-07-12 | 2011-02-11 | Provence Technologies | PROCESS FOR PURIFYING DIAMINOPHENOTHIAZIUM COMPOUNDS |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| EP2167095B1 (en) | 2007-06-19 | 2019-05-29 | WisTa Laboratories Ltd. | Phenothiazine compounds for treating mild cognitive impairment |
| MY161656A (en) * | 2007-10-03 | 2017-04-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiazines |
| WO2011036558A2 (en) | 2009-09-24 | 2011-03-31 | Wista Laboratories Ltd. | Crystalline methylthionium chloride (methylene blue) hydrates |
| WO2011036561A2 (en) | 2009-09-24 | 2011-03-31 | Wis Ta Laboratories Ltd. | Process |
| MY165906A (en) * | 2011-02-11 | 2018-05-18 | Wista Lab Ltd | Phenothiazine diaminium salts and their use |
| CN102936244B (en) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | Tacrine-phenothiazine isodiad compound and preparation method thereof |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 ES ES17761842T patent/ES2847929T3/en active Active
- 2017-08-25 PL PL17761842T patent/PL3506904T3/en unknown
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/en active
- 2017-08-25 SI SI201730630T patent/SI3506904T1/en unknown
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 MX MX2019002429A patent/MX2019002429A/en unknown
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/en active IP Right Grant
- 2017-08-25 PT PT177618428T patent/PT3506904T/en unknown
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/en active Active
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/en active Active
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en active Application Filing
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
-
2021
- 2021-02-01 HR HRP20210162TT patent/HRP20210162T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017318333B2 (en) | 2023-05-11 |
| ES2847929T3 (en) | 2021-08-04 |
| HRP20210162T1 (en) | 2021-03-19 |
| CN109890391A (en) | 2019-06-14 |
| KR102559354B1 (en) | 2023-07-26 |
| PL3506904T3 (en) | 2021-07-26 |
| MY187564A (en) | 2021-09-30 |
| US10842796B2 (en) | 2020-11-24 |
| WO2018041739A1 (en) | 2018-03-08 |
| JP7066679B2 (en) | 2022-05-13 |
| DK3506904T3 (en) | 2021-01-04 |
| EP3506904B1 (en) | 2020-12-09 |
| CN109890391B (en) | 2023-01-31 |
| PT3506904T (en) | 2021-02-02 |
| US20190192530A1 (en) | 2019-06-27 |
| AU2017318333A1 (en) | 2019-04-18 |
| SI3506904T1 (en) | 2021-03-31 |
| KR20190045273A (en) | 2019-05-02 |
| CA3034625A1 (en) | 2018-03-08 |
| GB201614834D0 (en) | 2016-10-19 |
| MX2019002429A (en) | 2019-07-08 |
| JP2019526571A (en) | 2019-09-19 |
| EP3506904A1 (en) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901125TA (en) | Treatment of dementia | |
| SG11201900228YA (en) | Administration and dosage of diaminophenothiazines | |
| SG11201807741SA (en) | Conductive structures, systems and devices including conductive structures and related methods | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201901210UA (en) | Ferroelectric memory cells | |
| SG11201906623SA (en) | A fluid-driven actuator and its applications | |
| SG11201809376WA (en) | Self assembled patterning using patterned hydrophobic surfaces | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201908075UA (en) | A microneedle device | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201809822SA (en) | Atropine-containing aqueous composition | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201806853VA (en) | Abstracted graphs from social relationship graph | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201900773RA (en) | Methods for optical micropatterning of hydrogels and uses thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |